EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte Studie

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

Julio Rosenstock iD, Stephen C Bain, Amoolya Gowda, Esteban Jódar, Bo Liang, Ildiko Lingvay iD, Tomoyuki Nishida, Roberto Trevisan, Ofri Mosenzon, ONWARDS 1 Trial Investigators

New England Journal of Medicine · 27.07.2023 · 389 (4) · 297-308

DOI: 10.1056/nejmoa2303208 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 27.07.2023. Verfasst von Julio Rosenstock und 9 weiteren Autor:innen. Beteiligte Einrichtung: From Velocity Clinical Research at Medical City (J.R.) and the Division of Endocrinology, Department of Internal Medicine, and the Peter O'Donnell Jr…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia, Hypoglycemic Agents, Insulin Glargine. Die Arbeit wurde bisher 161-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Novo Nordisk, Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HypoglycemiaHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingAdultHumansBlood GlucoseGlycated HemoglobinInsulinFollow-Up StudiesDrug Administration Schedule

Substanzen

Blood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinInsulin Glargineinsulin icodecInsulin, Long-Acting

Autor:innen und Institutionen

  • From Velocity Clinical Research at Medical City (J.R.) and the Division of Endocrinology, Department of Internal Medicine, and the Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Ce…

ORCID-Profile: Julio Rosenstock, Ildiko Lingvay

Förderung

  • Novo Nordisk
  • Novo Nordisk A/S

Zitieren

APA

Rosenstock, J., Bain, S. C., Gowda, A., Jódar, E., Liang, B., Lingvay, I., Nishida, T., Trevisan, R., Mosenzon, O., & ONWARDS 1 Trial Investigators (2023). Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. New England Journal of Medicine, 389(4), 297-308. https://doi.org/10.1056/nejmoa2303208

Vancouver

Rosenstock J, Bain SC, Gowda A, Jódar E, Liang B, Lingvay I, et al. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. New England Journal of Medicine. 2023;389(4):297-308. doi:10.1056/nejmoa2303208

BibTeX
@article{Rosenstock2023,
  author = {Rosenstock, Julio and Bain, Stephen C and Gowda, Amoolya and Jódar, Esteban and Liang, Bo and Lingvay, Ildiko and Nishida, Tomoyuki and Trevisan, Roberto and Mosenzon, Ofri and ONWARDS 1 Trial Investigators, ONWARDS 1 Trial Investigators},
  title = {Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {4},
  pages = {297--308},
  doi = {10.1056/nejmoa2303208}
}
Kostenlos starten →